Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)
Sponsor: Brii Biosciences Limited
Summary
This study will evaluate the efficacy and safety of the regimens containing BRII-179, BRII-835, and PEG-IFNα in adult participants with chronic hepatitis B virus (HBV) infection receiving nucleos(t)ide reverse transcriptase inhibitors (NRTIs) as background therapy.
Official title: A Phase 2 Multicenter, Open-label Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and Pegylated Interferon Alpha (PEG-IFNα) for the Treatment of Chronic Hepatitis B Virus (HBV) Infection (ENRICH)
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2024-08-06
Completion Date
2027-06
Last Updated
2024-12-30
Healthy Volunteers
No
Interventions
BRII-179
BRII-179 will be given via intramuscular injection
BRII-835 (VIR-2218)
BRII-835 will be given via subcutaneous injection
PEG-IFNα
PEG-IFNα will be given via subcutaneous injection
Locations (12)
Investigative Site 86004
Beijing, Beijing Municipality, China
Investigative Site 86009
Beijing, Beijing Municipality, China
Investigative Site 86015
Xiamen, Fujian, China
Investigative Site 86012
Foshan, Guangdong, China
Investigative Site 86001
Guangzhou, Guangdong, China
Investigative Site 86013
Guangzhou, Guangdong, China
Investigative Site 86002
Shenzhen, Guangdong, China
Investigative Site 86003
Shanghai, Shanghai Municipality, China
Investigative Site 86008
Shanghai, Shanghai Municipality, China
Investigative Site 86007
Chengdu, Sichuan, China
Investigative Site 86011
Chengdu, Sichuan, China
Investigative Site 86005
Hangzhou, Zhejiang, China